In August 2021, Tongji Hospital adjusted the hospital ethics committee and changed its record in China Medical Research Registry and Management System to further strengthen and standardize the management of ethical review of biomedical research involving human subjects, and improve the efficiency of ethical review.

Following the principle of independence, diversity, and transparency, the Medical Ethics Committee of Tongji Hospital carries out ethical reviews of drug clinical trials, medical device and reagent clinical trials, and other biomedical research involving human subjects conducted in the Hospital in accordance with the Declaration of Helsinki (2013), the Measures for the Ethical Review of Biomedical Research Involving Human Subjects (2016), the Good Clinical Practice (2020), the Good Clinical Practice for Medical Devices (2022), and other laws and regulations. The Medical Ethics Committee Office has one director and one secretary (part-time) who are responsible for the routine management of the Medical Ethics Committee. The Medical Ethics Committee reviews biomedical research involving human subjects to be conducted in the Hospital primarily through conference review and expedited review.

Any biomedical research involving human subjects to be conducted in the Hospital must be reviewed by the Medical Ethics Committee before its implementation and can be implemented only after it is approved by the Medical Ethics Committee. During the implementation of biomedical research involving human subjects, the Medical Ethics Committee will implement further follow-up and review as necessary to strengthen process supervision and management, ensure the safety and health of subjects and protect the rights and interests of subjects.